# Quantikine ELISA 

## Human Pappalysin-1/PAPP-A Immunoassay

Catalog Number DPPAOO

For the quantitative determination of human Pregnancy-Associated Plasma Protein-A (PAPP-A) concentrations in cell culture supernates, serum, and plasma.

This package insert must be read in its entirety before using this product.
For research use only. Not for use in diagnostic procedures.

## TABLE OF CONTENTS

SECTION ..... PAGE
INTRODUCTION ..... 1
PRINCIPLE OF THE ASSAY ..... 2
LIMITATIONS OF THE PROCEDURE .....  .2
TECHNICAL HINTS .....  .2
MATERIALS PROVIDED \& STORAGE CONDITIONS ..... 3
OTHER SUPPLIES REQUIRED ..... 3
PRECAUTIONS ..... 4
SAMPLE COLLECTION \& STORAGE ..... 4
REAGENT PREPARATION ..... 5
ASSAY PROCEDURE ..... 6
CALCULATION OF RESULTS ..... 7
TYPICAL DATA ..... 7
PRECISION ..... 8
RECOVERY ..... 8
LINEARITY ..... 8
SENSITIVITY ..... 9
CALIBRATION ..... 9
SAMPLE VALUES ..... 9
SPECIFICITY ..... 10
REFERENCES ..... 10
MANUFACTURED AND DISTRIBUTED BY:
USA \& Canada | R\&D Systems, Inc.614 McKinley Place NE, Minneapolis, MN 55413, USATEL: (800) 343-7475 (612) 379-2956 FAX: (612) 656-4400
E-MAIL: info@RnDSystems.com
DISTRIBUTED BY:
UK \& Europe \| R\&D Systems Europe, Ltd.19 Barton Lane, Abingdon Science Park, Abingdon OX14 3NB, UKTEL: +44 (0)1235 529449 FAX: +44 (0)1235 533420E-MAIL: info@RnDSystems.co.uk
China | R\&D Systems China Co., Ltd.24A1 Hua Min Empire Plaza, 726 West Yan An Road, Shanghai PRC 200050
TEL: +86 (21) 52380373 FAX: +86 (21) 52371001
E-MAIL: info@RnDSystemsChina.com.cn

## INTRODUCTION

Pregnancy-Associated Plasma Protein-A (PAPP-A), also known as Pappalysin-1, is a 400 kDa secreted, homodimeric glycoprotein that belongs to the metzincin superfamily of metalloproteases (1,2). It is best known as a regulator of IGF-II activity and plays a crucial role in placental development $(1,3)$. It is produced by a variety of primary cell types, including osteoblasts (4), vascular smooth muscle cells (5), fibroblasts (6), and follicular granulosa cells (7). The cells most associated with PAPP-A expression are endometrial stromal fibroblasts and extravillous trophoblasts (8-11). During placental growth, IGF-II seems to be the dominant insulin-like growth factor. It promotes steroidogenesis, glucose transport, and trophoblast (fetal tissue) invasion of the uterine endometrium (decidua). IGF-II is expressed by extraembryonic mesoderm and extravillous cytotrophoblasts (non-fetal cells that anchor the developing embryo to the uterine wall). Upon secretion, IGF-II activity is quickly downregulated through its binding to IGFBP-4 produced by adjacent decidual fibroblasts (9, 10,12 ). Activity is restored when IGF-II is released from IGFBP-4, a process that involves IGFBP-4 cleavage. PAPP-A is the enzyme responsible for this cleavage (13). It requires the presence of an IGF-II:IGFBP-4 complex and performs this action while non-covalently immobilized (presumably) on the surface of trophoblast cells ( 9,11 ). PAPP-A itself is negatively regulated by a membrane-associated formation of a pro-MBP (major basic protein):PAPP-A heterotetramer (2:2 ratio) $(14,15)$. Pro-MBP is a 50-90 kDa trophoblast-derived protein that forms multiple disulfide bonds with PAPP-A and induces its dissociation from the trophoblast cell membrane. This creates an inactive, circulating, 500 kDa PAPP-A heteromeric complex (1). Not all circulating PAPP-A is part of an inactive heterotetramer. Approximately $1 \%$ of PAPP-A in pregnancy sera exists as a proteolytically active 400 kDa homodimer and significant quantities of homodimer have been noted in acute coronary syndrome (1, 3, 11, 16).

Human PAPP-A is synthesized as a 1628 amino acid (aa) prepro-precursor that contains a 22 aa signal sequence, a 58 aa pro-segment, and a 1548 aa mature region (17-19). The mature region contains an N-terminal laminin G-like module that stabilizes an adjacent proteolytic domain. The proteolytic domain (aa 324-672) shows a histidine-rich zinc-binding motif plus two LNR repeats that participate in IGFBP-4 cleavage. Five CCP/SCR class III modules (aa 1215-1554) exist at the C-terminus. Upon secretion, SCR-3 and -4 are believed to anchor PAPP-A to the trophoblast cell surface by binding to cell membrane heparan sulfate polymers ( $1,11,20$ ). The PAPP-A 400 kDa homodimer consists of two parallel monomers linked by one disulfide bond (Cys1130-Cys1130). When pro-MBP combines with PAPP-A to generate an inhibitory 2:2 heterotetrameric complex, each pro-MBP monomer forms two disulfide bonds with its counterpart monomer and two disulfide bonds with one of the two PAPP-A monomers (Cys $381_{\text {PAPP-A }}-$ Cys51 $1_{\text {MBP }}$ and Cys652 $2_{\text {PAPP-A }}-$ Cys $169_{\text {MBP }}$ ) $(21,22)$. Over the mature region, human PAPP-A shows $91 \%$ aa sequence identity with mouse PAPP-A. There is one potential GenBank isoform of human PAPP-A that is 1232 aa in length. It shows an alternate start site at Met209 and a 22 aa substitution for the C-terminal 210 aa of the long form (23).

The Quantikine Human Pappalysin-1/PAPP-A Immunoassay is a 5.5 hour sandwich-type solid phase ELISA designed to measure human PAPP-A in cell culture supernates, serum, and plasma. It contains NS0-expressed recombinant human PAPP-A and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human PAPP-A showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human PAPP-A.

## PRINCIPLE OF THE ASSAY

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for human PAPP-A has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any PAPP-A present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked polyclonal antibody specific for human PAPP-A is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of PAPP-A bound in the initial step. The color development is stopped and the intensity of the color is measured.

## LIMITATIONS OF THE PROCEDURE

- FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
-The kit should not be used beyond the expiration date on the kit label.
- Do not mix or substitute reagents with those from other lots or sources.
- Samples must be pipetted within 15 minutes.
- If samples generate values higher than the highest standard, dilute the samples with Calibrator Diluent and repeat the assay.
- Any variation in standard diluent, operator, pipetting technique, washing technique, incubation time or temperature, and kit age can cause variation in binding.
- Variations in sample collection, processing, and storage may cause sample value differences.
-This assay is designed to eliminate interference by other factors present in biological samples. Until all factors have been tested in the Quantikine Immunoassay, the possibility of interference cannot be excluded.


## TECHNICAL HINTS

- When mixing or reconstituting protein solutions, always avoid foaming.
- To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.
- To ensure accurate results, proper adhesion of plate sealers during incubation steps is necessary.
- When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer, and/or rotating the plate 180 degrees between wash steps may improve assay precision.
- Substrate Solution should remain colorless until added to the plate. Keep Substrate Solution protected from light. Substrate Solution should change from colorless to gradations of blue.
- Stop Solution should be added to the plate in the same order as the Substrate Solution. The color developed in the wells will turn from blue to yellow upon addition of the Stop Solution. Wells that are green in color indicate that the Stop Solution has not mixed thoroughly with the Substrate Solution.


## MATERIALS PROVIDED \& STORAGE CONDITIONS

Store the unopened kit at $2-8^{\circ} \mathrm{C}$. Do not use past kit expiration date.

| PART | PART \# | DESCRIPTION | STORAGE OF OPENED/ RECONSTITUTED MATERIAL |
| :---: | :---: | :---: | :---: |
| Human PAPP-A Microplate | 893567 | 96 well polystyrene microplate ( 12 strips of 8 wells) coated with a monoclonal antibody specific for human PAPP-A. | Return unused wells to the foil pouch containing the desiccant pack. Reseal along entire edge of the zip-seal. May be stored for up to 1 month at $2-8^{\circ} \mathrm{C}$. ${ }^{*}$ |
| Human PAPP-A Conjugate | 893568 | 21 mL of polyclonal antibody specific for human PAPP-A conjugated to horseradish peroxidase with preservatives. | May be stored for up to 1 month at $2-8^{\circ} \mathrm{C} .{ }^{*}$ |
| Human PAPP-A Standard | 893569 | 500 ng of recombinant human PAPP-A in a buffered protein solution with preservatives; Iyophilized. |  |
| Assay Diluent RD1-15 | 895424 | 11 mL of a buffered protein base with preservative. |  |
| Calibrator Diluent RD6-14 | 895220 | 21 mL of a buffered protein base with preservatives. |  |
| Wash Buffer Concentrate | 895003 | 21 mL of a 25 -fold concentrated solution of buffered surfactant with preservative. May turn yellow over time. |  |
| Color Reagent A | 895000 | 12 mL of stabilized hydrogen peroxide. |  |
| Color Reagent B | 895001 | 12 mL of stabilized chromogen (tetramethylbenzidine). |  |
| Stop Solution | 895032 | 6 mL of 2 N sulfuric acid. |  |
| Plate Sealers | N/A | 4 adhesive strips. |  |

* Provided this is within the expiration date of the kit.


## OTHER SUPPLIES REQUIRED

- Microplate reader capable of measuring absorbance at 450 nm , with the correction wavelength set at 540 nm or 570 nm .
- Pipettes and pipette tips.
- Deionized or distilled water.
- Squirt bottle, manifold dispenser, or automated microplate washer.
- 500 mL graduated cylinder.
- Polypropylene test tubes for dilution of standards.
- Human PAPP-A Controls (optional; R\&D Systems, Catalog \# QC23).


## PRECAUTIONS

The Stop Solution provided with this kit is an acid solution.
Some components in this kit contain ProClin ${ }^{\circledR}$ which may cause an allergic skin reaction. Avoid breathing mist.

Color Reagent B may cause skin, eye, and respiratory irritation. Avoid breathing fumes.
Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling. Please refer to the MSDS on our website prior to use.

## SAMPLE COLLECTION \& STORAGE

The sample collection and storage conditions listed below are intended as general guidelines. Sample stability has not been evaluated.

Cell Culture Supernates - Remove particulates by centrifugation and assay immediately or aliquot and store samples at $\leq-20^{\circ} \mathrm{C}$. Avoid repeated freeze-thaw cycles.

Serum - Use a serum separator tube (SST) and allow samples to clot for 30 minutes at room temperature before centrifugation for 15 minutes at $1000 \times \mathrm{g}$. Remove serum and assay immediately or aliquot and store samples at $\leq-20^{\circ} \mathrm{C}$. Avoid repeated freeze-thaw cycles.

Plasma - Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge for 15 minutes at $1000 \times \mathrm{g}$ within 30 minutes of collection. Assay immediately or aliquot and store samples at $\leq-20^{\circ} \mathrm{C}$. Avoid repeated freeze-thaw cycles.

Note: Citrate plasma has not been validated for use in this assay.

All trademarks and registered trademarks are the property of their respective owners.

## REAGENT PREPARATION

## Bring all reagents to room temperature before use.

Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 20 mL of Wash Buffer Concentrate to deionized or distilled water to prepare 500 mL of Wash Buffer.

Substrate Solution - Color Reagents A and B should be mixed together in equal volumes within 15 minutes of use. Protect from light. $200 \mu \mathrm{~L}$ of the resultant mixture is required per well.

Human PAPP-A Standard - Reconstitute the Human PAPP-A Standard with 1.0 mL of deionized or distilled water. This reconstitution produces a stock solution of $500 \mathrm{ng} / \mathrm{mL}$. Mix the standard to ensure complete reconstitution and allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions.

Use polypropylene tubes. Pipette $900 \mu \mathrm{~L}$ of Calibrator Diluent RD6-14 into the $50 \mathrm{ng} / \mathrm{mL}$ tube. Pipette $500 \mu \mathrm{~L}$ of into the remaining tubes. Use the stock solution to produce a dilution series (below). Mix each tube thoroughly before the next transfer. The $50 \mathrm{ng} / \mathrm{mL}$ standard serves as the high standard. The Calibrator Diluent RD6-14 serves as the zero standard $(0 \mathrm{pg} / \mathrm{mL})$.


## ASSAY PROCEDURE

Bring all reagents and samples to room temperature before use. It is recommended that all samples, controls, and standards be assayed in duplicate.

Note: Strict adherence of the incubation times is critical to the performance of the assay.

1. Prepare all reagents, working standards, and samples as directed in the previous sections.
2. Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.
3. Add $100 \mu \mathrm{~L}$ of Assay Diluent RD1-15 to each well.
4. Add $50 \mu \mathrm{~L}$ of Standard, control, or sample per well. Note: Pipetting must be completed within 15 minutes. Cover with the adhesive strip provided. Incubate for $\mathbf{3}$ hours at room temperature.
5. Aspirate each well and wash, repeating the process three times for a total of four washes. Wash by filling each well with Wash Buffer ( $400 \mu \mathrm{~L}$ ) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
6. Add $200 \mu \mathrm{~L}$ of Human PAPP-A Conjugate to each well. Cover with a new adhesive strip. Incubate for $\mathbf{2}$ hours at room temperature.
7. Repeat the aspiration/wash as in step 5.
8. Add $200 \mu \mathrm{~L}$ of Substrate Solution to each well. Incubate for $\mathbf{3 0}$ minutes at room temperature. Protect from light.
9. Add $50 \mu \mathrm{~L}$ of Stop Solution to each well. The color in the wells should change from blue to yellow. If the color in the wells is green or the color change does not appear uniform, gently tap the plate to ensure thorough mixing.
10. Determine the optical density of each well within 30 minutes using a microplate reader set to 450 nm . If wavelength correction is available, set to 540 nm or 570 nm . If wavelength correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm . This subtraction will correct for optical imperfections in the plate. Readings made directly at 450 nm without correction may be higher and less accurate.

## CALCULATION OF RESULTS

Average the duplicate readings for each standard, control, and sample and subtract the average zero standard optical density (O.D.).

Create a standard curve by reducing the data using computer software capable of generating a log/log curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on a log/log graph. The data may be linearized by plotting the log of the human PAPP-A concentrations versus the log of the O.D. on a linear scale, and the best fit line can be determined by regression analysis.

If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

## TYPICAL DATA

This standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed.


| (ng/mL) | $0 . \mathrm{D}$. | Average | Corrected |
| :---: | :---: | :---: | :---: |
| 0 | 0.011 | 0.011 | - |
|  | 0.011 |  |  |
| 0.78 | 0.059 | 0.060 | 0.049 |
|  | 0.060 |  |  |
| 1.56 | 0.105 | 0.107 | 0.096 |
|  | 0.08 |  |  |
| 3.13 | 0.199 | 0.207 | 0.196 |
|  | 0.214 |  |  |
| 6.25 | 0.391 | 0.401 | 0.390 |
|  | 0.411 |  |  |
| 12.5 | 0.763 | 0.779 | 0.768 |
|  | 0.795 |  |  |
| 25 | 1.448 | 1.481 | 1.470 |
|  | 1.514 |  |  |
| 50 | 2.682 | 2.706 | 2.695 |
|  | 2.729 |  |  |

## PRECISION

## Intra-assay Precision (Precision within an assay)

Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

## Inter-assay Precision (Precision between assays)

Three samples of known concentration were tested in forty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.

|  | Intra-Assay Precision |  |  | Inter-Assay Precision |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| $\mathbf{n}$ | 20 | 20 | 20 | 40 | 40 | 40 |
| Mean (ng/mL) | 5.49 | 17.4 | 32.7 | 5.20 | 16.4 | 31.4 |
| Standard deviation | 0.32 | 0.78 | 1.39 | 0.44 | 1.14 | 2.04 |
| CV (\%) | 5.8 | 4.5 | 4.3 | 8.5 | 7.0 | 6.5 |

## RECOVERY

The recovery of human PAPP-A spiked to levels throughout the range of the assay in various matrices was evaluated.

| Sample Type | Average \% Recovery | Range |
| :--- | :---: | :---: |
| Cell culture media $(\mathrm{n}=4)$ | 110 | $90-117 \%$ |
| Serum $(\mathrm{n}=4)$ | 92 | $84-104 \%$ |
| EDTA plasma $(\mathrm{n}=4)$ | 97 | $89-108 \%$ |
| Heparin plasma $(\mathrm{n}=4)$ | 95 | $86-111 \%$ |

## LINEARITY

To assess the linearity of the assay, samples containing and/or spiked with high concentrations of human PAPP-A were diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.

|  |  | Cell culture <br> media <br> $(n=4)$ | Serum <br> $(n=8)$ | EDTA <br> plasma <br> $(n=4)$ | Heparin <br> plasma <br> $(n=4)$ |
| :---: | :--- | :--- | :--- | :--- | :--- |
|  |  | 102 | 104 | 105 | 100 |
|  | Range (\%) | $101-104$ | $99-111$ | $99-112$ | $97-106$ |
| $1: 4$ | Average \% of Expected | 100 | 108 | 105 | 108 |
|  | Range (\%) | $97-103$ | $100-114$ | $103-114$ | $105-114$ |
| $1: 8$ | Average \% of Expected | 97 | 107 | 107 | 111 |
|  | Range (\%) | $96-98$ | $93-117$ | $101-114$ | $109-115$ |
| $1: 16$ | Average \% of Expected | 93 | 102 | 107 | 111 |
|  | Range (\%) | $90-96$ | $92-110$ | $95-115$ | $106-116$ |

## SENSITIVITY

Fifty assays were evaluated and the minimum detectable dose (MDD) of human PAPP-A ranged from $0.015-0.116 \mathrm{ng} / \mathrm{mL}$. The mean MDD was $0.053 \mathrm{ng} / \mathrm{mL}$.

The MDD was determined by adding two standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration.

## CALIBRATION

This immunoassay is calibrated against a highly purified NSO-expressed recombinant human PAPP-A produced at R\&D Systems.

## SAMPLE VALUES

## Serum/Plasma:

Thirty-six serum and plasma samples from non-pregnant donors were evaluated for the presence of human PAPP-A in this assay. No detectable levels were observed. No medical histories were available for the donors used in this study.

Thirty pregnancy sera ranging from 6-40 weeks gestation were tested for human PAPP-A. Sample values ranged from non-detectable to $325 \mathrm{ng} / \mathrm{mL}$.

Cell Culture Supernates - Human peripheral blood mononuclear cells ( $1 \times 10^{6}$ cells $/ \mathrm{mL}$ ) were cultured in DMEM supplemented with $5 \%$ fetal calf serum, $5 \mu \mathrm{M} \beta$-mercaptoethanol, 2 mM L-glutamine, $100 \mathrm{U} / \mathrm{mL}$ penicillin, and $100 \mu \mathrm{~g} / \mathrm{mL}$ streptomycin sulfate. Cells were cultured unstimulated or stimulated with $10 \mu \mathrm{~g} / \mathrm{mL}$ PHA for 1 and 5 days. Aliquots of the cell culture supernate were removed and assayed for human PAPP-A. No detectable levels were observed.

## SPECIFICITY

This assay recognizes natural and recombinant human PAPP-A.
The factors listed below were prepared at $500 \mathrm{ng} / \mathrm{mL}$ in Calibrator Diluent and assayed for cross-reactivity. Preparations of the following factors at $500 \mathrm{ng} / \mathrm{mL}$ in a mid-range recombinant human PAPP-A control were assayed for interference. No significant cross-reactivity or interference was observed.

## Recombinant human: Natural protein:

IGFBP-4
human a2-macroglobulin
IGFBP-5
MBP-1
PAPP-A2
Serpin A8

## REFERENCES

1. Boldt, H.B. and C.A. Conover (2007) Growth Horm. \& IGF Res. 17:10.
2. Boldt, H.B. et al. (2001) Biochem. J. 358:359.
3. Qin, Q.P. et al. (2007) Clin. Chim. Acta 380:59.
4. Ortiz, C.O. et al. (2003) J. Bone Miner. Res. 18:1066.
5. Conover, C.A. et al. (2006) Am. J. Physiol. Cell Physiol. 290:C183.
6. Chen, B-K. et al. (2002) Endocrinology 143:1199.
7. Conover, C.A. et al. (1999) J. Clin. Endocrinol. Metab. 84:4742.
8. Wasmoen, T.L. et al. (1989) J. Exp. Med. 170:2051.
9. Sun, I.Y.C. et al. (2002) J. Clin. Endocrinol. Metab. 87:5235.
10. Giudice, L.C. et al. (2002) J. Clin. Endocrinol. Metab. 87:2359.
11. Glerup, S. et al. (2007) J. Biol. Chem. 282:1769.
12. Han, V.K.M. et al. (1996) J. Clin. Endocrinol. Metab. 81:2680.
13. Conover, C.A. et al. (1993) J. Clin. Invest. 91:1129.
14. Overgaard, M.T. et al. (2004) FEBS Lett. 560:147.
15. Oxvig, C. et al. (1993) J. Biol. Chem. 268:12243.
16. Overgaard, M.T. et al. (2000) J. Biol. Chem. 275:31128.
17. Haaning, J. et al. (1996) Eur. J. Biochem. 237:159.
18. Kristensen, T. et al. (1994) Biochemistry 33:1592.
19. Lawrence, J.B. et al. (1999) Proc. NatI. Acad. Sci. USA 96:3149.
20. Weyer, K. et al. (2004) Eur. J. Biochem. 271:1525.
21. Overgaard, M.T. et al. (2003) J. Biol. Chem. 278:2106.
22. Glerup, S. et al. (2005) J. Biol. Chem. 280:9823.
23. GenBank Accession \# EAW87441.15.

|  | O2014 R\&D Systems, Inc. |  |
| :--- | :--- | :--- |
| 10.07 | 751853.2 | $9 / 14$ |

